Yi-Yao Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi-Yao Chang has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Vin-Cent Wu
Division of Nephrology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
9 shared publications - Yen-Hung Lin
National Taiwan University Hospital
9 shared publications - Chi-Sheng Hung
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
7 shared publications - Bo-Ching Lee
National Taiwan University Hospital
6 shared publications - Cheng-Hsuan Tsai
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
6 shared publications - Che-Wei Liao
Department of Internal Medicine, Division of Cardiology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei 100, Taiwan
5 shared publications
Latest Publications
- Open Access
Fibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
Open AccessFibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
- Open Access
Effectiveness and Safety of Bempedoic Acid Across Clinically Relevant Subgroups: Insights from the CLEAR Taiwan Study
Background Despite available lipid-lowering therapies (LLT), many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets. This gap persists across clinically relevant subgroups. Bempedoic acid has demonstrated effective LDL-C lowering with a favorable safety profile in the CLEAR Taiwan study; however, its effects across subgroups in Asian populations remains limited. Methods The phase IV CLEAR Taiwan study ( NCT06925100 ) enrolled patients with inadequately controlled hypercholesterolemia who received bempedoic acid for 12 weeks in addition to background LLT. This analysis evaluated changes in lipid parameters, high-sensitivity C-reactive protein (hsCRP), and safety outcomes in clinically relevant subgroups, including cardiovascular risk, diabetes, age, statin tolerance, and sex. Results A total of 180 patients were included. Bempedoic acid achieved significant LDL-C reductions in all subgroups. Numerically greater LDL-C reductions were observed in primary prevention, statin-intolerant, younger (< 65 years), and female patients, while comparable reductions were observed across diabetes status. Reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B were consistent with LDL-C findings. Significant decreases in hsCRP were observed in all subgroups, with numerically greater reductions in patients aged < 65 years and those without diabetes. Bempedoic acid was well tolerated, with a low incidence of adverse events and no new safety signals identified. Changes in liver enzymes, renal function, and uric acid were minimal within subgroups. Conclusion Subgroup analyses from the CLEAR Taiwan study demonstrate consistent efficacy and safety of bempedoic acid across clinically relevant subgroups and support its use as a flexible option to address residual gaps in lipid management.
Open AccessEffectiveness and Safety of Bempedoic Acid Across Clinically Relevant Subgroups: Insights from the CLEAR Taiwan Study
Background Despite available lipid-lowering therapies (LLT), many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets. This gap persists across clinically relevant subgroups. Bempedoic acid has demonstrated effective LDL-C lowering with a favorable safety profile in the CLEAR Taiwan study; however, its effects across subgroups in Asian populations remains limited. Methods The phase IV CLEAR Taiwan study ( NCT06925100 ) enrolled patients with inadequately controlled hypercholesterolemia who received bempedoic acid for 12 weeks in addition to background LLT. This analysis evaluated changes in lipid parameters, high-sensitivity C-reactive protein (hsCRP), and safety outcomes in clinically relevant subgroups, including cardiovascular risk, diabetes, age, statin tolerance, and sex. Results A total of 180 patients were included. Bempedoic acid achieved significant LDL-C reductions in all subgroups. Numerically greater LDL-C reductions were observed in primary prevention, statin-intolerant, younger (< 65 years), and female patients, while comparable reductions were observed across diabetes status. Reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B were consistent with LDL-C findings. Significant decreases in hsCRP were observed in all subgroups, with numerically greater reductions in patients aged < 65 years and those without diabetes. Bempedoic acid was well tolerated, with a low incidence of adverse events and no new safety signals identified. Changes in liver enzymes, renal function, and uric acid were minimal within subgroups. Conclusion Subgroup analyses from the CLEAR Taiwan study demonstrate consistent efficacy and safety of bempedoic acid across clinically relevant subgroups and support its use as a flexible option to address residual gaps in lipid management.
- Open Access
Recognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
Open AccessRecognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e049917
Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study)
Background: Elevated low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for cardiovascular disease. Despite available lipid‐lowering therapies, lipid control remains suboptimal. Bempedoic acid offers a nonstatin oral treatment for hypercholesterolemia. However, real‐world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. Methods: This prospective, pragmatic phase 4 study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background lipid‐lowering therapy. The primary end point was the percentage change in LDL‐C. Secondary end points included changes in other lipid parameters, hs‐CRP (high‐sensitivity C‐reactive protein), and safety outcomes. Results: Among 180 patients, 160 (88.9%) completed the study. The median percentage change in LDL‐C from baseline to week 12 was −19% (interquartile range, −36.4% to −3.6%), decreasing from 117.5 to 92 mg/dL ( P P 0.05). At week 12, 31.3% of patients achieved LDL‐C targets (<100 mg/dL for primary prevention; and <55 or <70 mg/dL for secondary prevention). The safety outcomes were consistent with the locally approved label, with no new safety signals identified. Conclusions: Bempedoic acid offers an effective and safe oral therapeutic option for Taiwanese patients whose LDL‐C levels remain inadequately controlled with existing lipid‐lowering therapy, including statins. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT06925100.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e049917
Open AccessEffectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study)
Background: Elevated low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for cardiovascular disease. Despite available lipid‐lowering therapies, lipid control remains suboptimal. Bempedoic acid offers a nonstatin oral treatment for hypercholesterolemia. However, real‐world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. Methods: This prospective, pragmatic phase 4 study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background lipid‐lowering therapy. The primary end point was the percentage change in LDL‐C. Secondary end points included changes in other lipid parameters, hs‐CRP (high‐sensitivity C‐reactive protein), and safety outcomes. Results: Among 180 patients, 160 (88.9%) completed the study. The median percentage change in LDL‐C from baseline to week 12 was −19% (interquartile range, −36.4% to −3.6%), decreasing from 117.5 to 92 mg/dL ( P P 0.05). At week 12, 31.3% of patients achieved LDL‐C targets (<100 mg/dL for primary prevention; and <55 or <70 mg/dL for secondary prevention). The safety outcomes were consistent with the locally approved label, with no new safety signals identified. Conclusions: Bempedoic acid offers an effective and safe oral therapeutic option for Taiwanese patients whose LDL‐C levels remain inadequately controlled with existing lipid‐lowering therapy, including statins. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT06925100.
- 1 May 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (5)
Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism
BACKGROUND: Sex differences influence cardiovascular risk assessment and management; however, their role in aldosterone-mediated cardiac remodeling in primary aldosteronism remains incompletely understood. METHODS: We conducted a retrospective study of 547 patients with primary aldosteronism, including 249 men and 298 women. Clinical and echocardiographic data were collected at baseline and 1 year following aldosterone-targeted therapies. RESULTS: The mean age was 53.8 years in men and 54.6 years in women. At baseline, men had a higher left ventricular mass index (LVMI), whereas women had a higher prevalence of left ventricular (LV) hypertrophy and worse diastolic function, as indicated by a higher ratio of early diastolic transmitral to mitral annular velocity (E/e′) and left atrial volume index. In multivariable analyses, plasma aldosterone concentration (PAC) was associated with baseline LVMI in both sexes. Associations between PAC and baseline diastolic indices, including E/e′ and left atrial volume index, were observed in men but not in women in sex-stratified models. However, formal interaction testing did not demonstrate significant sex-by- PAC interactions for left atrial volume index, E/e′, or LAVI. After 1 year of treatment, LVMI reduction was comparable between sexes. Improvement in E/e′ was significantly less pronounced in women. LAVI decreased significantly in men but not in women, although between-sex differences in change were not statistically significant. CONCLUSIONS: Sex-specific differences in cardiac remodeling and diastolic function were observed in patients with primary aldosteronism. Despite lower baseline LVMI, women exhibited a more adverse cardiac phenotype, with a higher prevalence of left ventricular hypertrophy and worse diastolic function. Following aldosterone-targeted therapies, structural regression was similar between sexes, whereas diastolic function improved to a lesser extent in women.
- 1 May 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (5)
Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism
BACKGROUND: Sex differences influence cardiovascular risk assessment and management; however, their role in aldosterone-mediated cardiac remodeling in primary aldosteronism remains incompletely understood. METHODS: We conducted a retrospective study of 547 patients with primary aldosteronism, including 249 men and 298 women. Clinical and echocardiographic data were collected at baseline and 1 year following aldosterone-targeted therapies. RESULTS: The mean age was 53.8 years in men and 54.6 years in women. At baseline, men had a higher left ventricular mass index (LVMI), whereas women had a higher prevalence of left ventricular (LV) hypertrophy and worse diastolic function, as indicated by a higher ratio of early diastolic transmitral to mitral annular velocity (E/e′) and left atrial volume index. In multivariable analyses, plasma aldosterone concentration (PAC) was associated with baseline LVMI in both sexes. Associations between PAC and baseline diastolic indices, including E/e′ and left atrial volume index, were observed in men but not in women in sex-stratified models. However, formal interaction testing did not demonstrate significant sex-by- PAC interactions for left atrial volume index, E/e′, or LAVI. After 1 year of treatment, LVMI reduction was comparable between sexes. Improvement in E/e′ was significantly less pronounced in women. LAVI decreased significantly in men but not in women, although between-sex differences in change were not statistically significant. CONCLUSIONS: Sex-specific differences in cardiac remodeling and diastolic function were observed in patients with primary aldosteronism. Despite lower baseline LVMI, women exhibited a more adverse cardiac phenotype, with a higher prevalence of left ventricular hypertrophy and worse diastolic function. Following aldosterone-targeted therapies, structural regression was similar between sexes, whereas diastolic function improved to a lesser extent in women.
- Open Access
Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients with Hypercholesterolemia ― A Pragmatic Phase IV Study (CLEAR Taiwan Study)
Background: Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease. Despite available lipid-lowering therapies (LLT), lipid control remains suboptimal. Bempedoic acid offers a non-statin oral treatment for hypercholesterolemia. However, real-world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. Methods: This pragmatic phase IV study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background LLT. The primary endpoint was the percentage change in LDL-C. Secondary endpoints included changes in other lipid parameters, high-sensitivity C-reactive protein (hsCRP), and safety outcomes. Results: Among 180 patients, 160 (88.9%) completed the study. The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL ( p < 0.01). The median percentage changes from baseline to week 12 were -13.3% for non-high-density lipoprotein cholesterol (non-HDL-C), -10.8% for total cholesterol, -11.5% for apolipoprotein B, and -34.0% for hsCRP (all p < 0.01). Minimal effects were noted on triglycerides (+0.2%), HDL-C (-5.5%), and lipoprotein(a) (+2.6%) (all p > 0.05). At week 12, 31.3% of patients achieved LDL-C targets (< 100 mg/dL for primary prevention; < 55 or < 70 mg/dL for secondary prevention). The safety outcomes were consistent with the locally approved label, with no new safety signals identified. Conclusions: Bempedoic acid offers an effective and safe oral therapeutic option for Taiwanese patients whose LDL-C levels remain inadequately controlled with existing LLT, including statins. Registration: URL: https://clinicaltrials.gov/study/NCT06925100 ; Unique identifier: NCT06925100 Clinical Perspective: What Is New?: ◆ This pragmatic phase IV study provides the first real-world evidence from Taiwan demonstrating that bempedoic acid leads to clinically meaningful reductions in LDL-C (median percentage change: -19%) at week 12 when added to background lipid-lowering therapy in patients with inadequately controlled hypercholesterolemia. ◆ Approximately one-third of patients achieved guideline-recommended LDL-C targets within 12 weeks, with a safety profile consistent with the locally approved label and no new safety signals identified. What Are the Clinical Implications?: ◆ Bempedoic acid represents an effective and well-tolerated oral add-on lipid-lowering option for Taiwanese patients who fail to achieve LDL-C goals with existing therapies, including those unable to tolerate or intensify statin treatment.
Open AccessEffectiveness and Safety of Bempedoic Acid in Taiwanese Patients with Hypercholesterolemia ― A Pragmatic Phase IV Study (CLEAR Taiwan Study)
Background: Elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular disease. Despite available lipid-lowering therapies (LLT), lipid control remains suboptimal. Bempedoic acid offers a non-statin oral treatment for hypercholesterolemia. However, real-world data in Asia are limited. The study aimed to investigate the effectiveness and safety of bempedoic acid in Taiwan. Methods: This pragmatic phase IV study enrolled 180 patients with inadequately controlled hypercholesterolemia to receive bempedoic acid for 12 weeks in addition to background LLT. The primary endpoint was the percentage change in LDL-C. Secondary endpoints included changes in other lipid parameters, high-sensitivity C-reactive protein (hsCRP), and safety outcomes. Results: Among 180 patients, 160 (88.9%) completed the study. The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL ( p < 0.01). The median percentage changes from baseline to week 12 were -13.3% for non-high-density lipoprotein cholesterol (non-HDL-C), -10.8% for total cholesterol, -11.5% for apolipoprotein B, and -34.0% for hsCRP (all p < 0.01). Minimal effects were noted on triglycerides (+0.2%), HDL-C (-5.5%), and lipoprotein(a) (+2.6%) (all p > 0.05). At week 12, 31.3% of patients achieved LDL-C targets (< 100 mg/dL for primary prevention; < 55 or < 70 mg/dL for secondary prevention). The safety outcomes were consistent with the locally approved label, with no new safety signals identified. Conclusions: Bempedoic acid offers an effective and safe oral therapeutic option for Taiwanese patients whose LDL-C levels remain inadequately controlled with existing LLT, including statins. Registration: URL: https://clinicaltrials.gov/study/NCT06925100 ; Unique identifier: NCT06925100 Clinical Perspective: What Is New?: ◆ This pragmatic phase IV study provides the first real-world evidence from Taiwan demonstrating that bempedoic acid leads to clinically meaningful reductions in LDL-C (median percentage change: -19%) at week 12 when added to background lipid-lowering therapy in patients with inadequately controlled hypercholesterolemia. ◆ Approximately one-third of patients achieved guideline-recommended LDL-C targets within 12 weeks, with a safety profile consistent with the locally approved label and no new safety signals identified. What Are the Clinical Implications?: ◆ Bempedoic acid represents an effective and well-tolerated oral add-on lipid-lowering option for Taiwanese patients who fail to achieve LDL-C goals with existing therapies, including those unable to tolerate or intensify statin treatment.
- Open Access
- 6 November 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124, S32-S41
Lifestyle modifications and non-pharmacological management in elderly hypertension
- 6 November 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124, S32-S41
Open AccessLifestyle modifications and non-pharmacological management in elderly hypertension
- Open Access
- 7 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S91-S97
How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
- 7 June 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S91-S97
Open AccessHow should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 14
Synergistic effect of albuminuria on atherosclerosis in patients with primary aldosteronism
Background: Primary aldosteronism (PA) has been associated with atherosclerosis beyond the extent of essential hypertension, but the impact of albuminuria remains unknown. Objective: To investigate the effect of concomitant albuminuria on arterial stiffness in PA. Design: Prospective cohort study. Methods: A prospective cohort study was conducted to evaluate the association of albuminuria (>30 mg/g in morning spot urine) with arterial stiffness, as measured non-invasively by pulse wave velocity (PWV) in patients with PA. Propensity score matching (PSM) with age, sex, diabetes, systolic and diastolic blood pressure, creatinine, potassium, number of antihypertensive medications, and hypertension history was used to balance baseline characteristics. The effects of albuminuria on PWV before and 1 year after treatment were analyzed. Results: A total of 840 patients with PA were enrolled, of whom 243 had concomitant albuminuria. After PSM, there were no significant differences in baseline demographic parameters except alpha-blocker and spironolactone use. PWV was greater in the presence of albuminuria ( p = 0.012) and positively correlated with urine albumin–creatinine ratio. Multivariable regression analysis identified albuminuria, age, body weight, systolic blood pressure, and calcium channel blocker use as independent predictors of PWV. As for treatment response, only PA patients with albuminuria showed significant improvements in PWV after PSM ( p = 0.001). The magnitude of improvement in PWV increased with urine albumin–creatinine ratio and reached plateau when it exceeded 100 mg/g according to restricted cubic spline analysis. Conclusion: Concomitant albuminuria in PA was associated with greater arterial stiffness and more substantial improvement after targeted treatment. Both the baseline and the improved extent of PWV increased in correlation with rising urine albumin–creatinine ratio levels, reaching a plateau when the urine albumin–creatinine ratio surpassed 100 mg/g.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 14
Open AccessSynergistic effect of albuminuria on atherosclerosis in patients with primary aldosteronism
Background: Primary aldosteronism (PA) has been associated with atherosclerosis beyond the extent of essential hypertension, but the impact of albuminuria remains unknown. Objective: To investigate the effect of concomitant albuminuria on arterial stiffness in PA. Design: Prospective cohort study. Methods: A prospective cohort study was conducted to evaluate the association of albuminuria (>30 mg/g in morning spot urine) with arterial stiffness, as measured non-invasively by pulse wave velocity (PWV) in patients with PA. Propensity score matching (PSM) with age, sex, diabetes, systolic and diastolic blood pressure, creatinine, potassium, number of antihypertensive medications, and hypertension history was used to balance baseline characteristics. The effects of albuminuria on PWV before and 1 year after treatment were analyzed. Results: A total of 840 patients with PA were enrolled, of whom 243 had concomitant albuminuria. After PSM, there were no significant differences in baseline demographic parameters except alpha-blocker and spironolactone use. PWV was greater in the presence of albuminuria ( p = 0.012) and positively correlated with urine albumin–creatinine ratio. Multivariable regression analysis identified albuminuria, age, body weight, systolic blood pressure, and calcium channel blocker use as independent predictors of PWV. As for treatment response, only PA patients with albuminuria showed significant improvements in PWV after PSM ( p = 0.001). The magnitude of improvement in PWV increased with urine albumin–creatinine ratio and reached plateau when it exceeded 100 mg/g according to restricted cubic spline analysis. Conclusion: Concomitant albuminuria in PA was associated with greater arterial stiffness and more substantial improvement after targeted treatment. Both the baseline and the improved extent of PWV increased in correlation with rising urine albumin–creatinine ratio levels, reaching a plateau when the urine albumin–creatinine ratio surpassed 100 mg/g.
- 1 January 2022
- Published by Elsevier in Translational Research
- Vol. 239, 58-70
Aldosterone suppresses cardiac mitochondria
- 1 January 2022
- Published by Elsevier in Translational Research
- Vol. 239, 58-70
Aldosterone suppresses cardiac mitochondria